

Physical Exam Findings	
► Airway obstruction can cause shortness of breath	
➤ Wheezing and chest tightness	
► Prolonged expiratory phase	
► In children-flaring of nostrils, increased heart rate and cyanosis	
➤ In severe cases-no wheezing auscultated if all the breath sounds are reduced (ominous sign)	
#POFPS43	

	Osteopathic Exam Findi	ngs
	<ul> <li>Viscero-somatic reflexes in T1-T5/6 region bilaterally</li> </ul>	► Tissue texture changes to the thoracic area
	➤ Somatic dysfunction involving OA-C2	► Inhalation Rib dysfunction
1	► Hypertonicity of C3-C5	► Restrictive movement of the scapula
	► Chapman's reflexes	➤ Edema/Restriction of the thoracic inlet

## Treatment-Medications Controller medications are the foundation of care in asthmatic patients Inhaled corticosteroids are the preferred controller medication - when used consistently they improve asthma control more than other long-term control medication Beclomethasone, Budesonide, Fluticasone, Mometasone improvement in asthma symptoms can be seen in 1-3 weeks; best results in 3 months Combining long-acting beta2 agonists and inhaled corticosteroids is effective and safe when add on therapy is needed Formoterol (usually in combo w/Bedesonide), Salmeterol (Fluticasone), Vilanterol (Fluticasone) have an action of more than 12-24 hours


	Treatment-Medications
	► Leukotriene receptor antagonists can be used as adjunctive w/ inhaled corticosteroids but for persons >12 years of age addition of long acting- beta 2 agonist is preferred
	➤ Zileuton (leukotriene synthesis inhibitor) has been shown to improve peak flows
	Long acting Breaz apprists and Leukotriene modifiers - Montelukast (Singulair), Zaffrlukast (Accolate)
	► Short acting beta2 agonists should be used for rapid reversal of airflow obstruction and prompt relief of symptoms
N	➤ Albuterol, levalbuterol and pirbuterol
l	▶ onset of action of ≤5 minutes; peaking in 30-60 minutes; duration 4-6 hours
	#POFPS43



# Management-Acute exacerbation At home, assess peak flow-if <50.79% of their personal best, then give up to two treatments of 2-6 inhalations of short-acting beta2 agonists 20 minutes apart and then should recheck their peak flow In ED or ambulatory care, goal is correction of severe hypoxemia, reversal of airflow obstruction and reduce of risk of relapse Multiple doses of inhaled anticholinergics with beta2 agonist improve lung function and decrease hospitalization in school aged children Intravenous magnesium sulfate has been shown to significantly increase lung function and decrease hospitalization in children Administration of systemic steroids within one hour of presentation has also shown to decrease hospitalization


### Management-Long term Reduce impairment Reduce risk Reduce risk Assess asthma control to determine if therapy should be adjusted written asthma plans proper medication techniques patient adherence and concerns Obtain spirometry every 1-2 years

## Management-Long term • Develop written asthma action plan; new plan asthma APGAR tool (Activities, Persistent, triGGers, Asthma medications, Response to therapy) • Teach patients how to manage their asthma - self monitoring through symptoms or peak flow monitoring • Taking medications correctly and educating between controller and fast acting medications • Develop written action plan • Recommend ways to control exposures to allergens, irritants and pollutants • Discussing occupational exposure • Making sure if there are smokers at home that they smoke outside the house




N	Nanagement-New horizons			
	NIH study on a new pathway for asthma			
	About half the asthmatics will have type 2 high asthma which is caused by increase in eosinophils; in these patients standard asthma medications don't work but immunotherapy does work			
	Currently led by Dr Stewart Levine apolipoprotein A-1 is being studied and show that they can regulate the severity of asthma	M		
	It was shown that inhalation of 5A apolipoprotein A-1 mimetic peptide prevented allergic lung inflammation in asthmatic mice who lacked their own apolipoprotein A-1			
	The next step is to see if this will help in humans their preliminary studies have shown higher levels of Apolipoproetin A-1 in asthmatic patients were associated with better lung function			
Art	icle adapted from www.nih.gov			
#1	POFPS43		XV	١

### Management-Osteopathic Manipulation Next we will move on the hands on treatment of asthma Dr Margaret Wilkins DO will be assisting me she is Director of Faculty Development at PCOM MedNet OPTI and Clinical Associate Professor of Family Medicine What is the evidence? Reviewed article from the JAOA on "Effects of Osteopathic Manipulative treatment on Pediatric Patients with Asthma: Randomized Controlled Trial" OMT was shown to Improve peak flow from 71. per minute to 91. per minute OMM techniques have been shown to increase vital capacity and rib cage mobility, improve diaphragmatic function and enhance clearing of airway secretions



























































	References
	<ol> <li>Guiney PA, Chou R, Vianna A, Lovenheim J. Effects of Osteopathic Manipulative Treatment on Pediatric Patients with Asthma- A randomized controlled trial. J Am Osteopoth Assoc. 2005;105; 7-12</li> </ol>
	<ol> <li>Bockenhauer Se, Juliand KN, Io KS, Huang E, Sheth A. Quantifiable effects of osteopathic manipulative techniques on patients with chronic arthma. J Am Osteopath Assoc. 2002; 10:371-375.</li> </ol>
	1. Edward KS, Pollart SM. Medical Therapy for Asthma: Updates from NAEPP Guidelines. American Academy of Family Physicians. 2010; 82: 12-Q-1251.
	<ul> <li>National Heart, Lung and Blood Institute. Practical guide for Diagnosis and Management of Asthma/National Asthma Education and Prevention Report]</li> <li>Bland on the Expert Plant report 3 Solidelines for the diagnosis and Nanagement of Asthma. 3HH. Bethedda Maryland. October 2007. Available asthqtp: //www.hibbull.ag/or/hearty porf lung in practice point</li> </ul>
	5. Pollart SM, Comptom RM, Elward KS. Management of Acute Asthma Exacerbations. American Academy of Family Physicians. 2011;84: 40-47
1	<ol> <li>Pollart SM, Elward KS. Overview of Changes to Asthma Guidelines: Diagnosis and Screening. American Academy of Family Physicians. 2009;79(9):161-767</li> </ol>
١.	7. Falk NP, Hughes SW, Rodgers BC. Medications for Chronic Asthma. American Academy of Family Physicians. 2016;94(6):454-462
ı	s. Yawn BP, Wollan PC,Rank MA, Bertram St, Juhn Y, Pace, W. Use of Asthma Appar Tools in Primary Care Practices: A Cluster-Randomized Controlled Trial. Annals of Family Medicine. 2018;16: 100-110
	9. Fanta CH. Asthma Drug therapy. The New England Journal of Medicine. 2009;360:1002-14
	10. Nicholas As, Nicholas EA. Atlas of Osteopathic Techniques. Second Edition. 2013;79-105; 121-129;502-510.
	11. Guiney PA, Chou R, Vianna A, Lovenheim J. Effects of Osteopathic Manipulative Treatment on Pediatric Patients With Astrina: A Randomized
	Controlled Trial. The Journal of the American Osteopathic Association. 2005; Vol. 105, 7-12.
	#POFPS43

